Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

TEVA is down from $70 to $36. It is crazy that the market thinks Teva is going to lose all of its Copaxone sales (if not, why has the stock been cut in half) and yet thinks MNTA / NVS will sell none of the 40 mg Copaxone.

Not all of TEVA's sell-off is attributable to Copaxone. Other issues for TEVA are: i) overpaying for AGN's generic-drug business; and ii) negative year-over-year price growth for US generic drugs.